Stock A016450 HANSAE YES24 HOLDINGS CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Hansae Yes24 Holdings Co., Ltd

Equities

A016450

KR7016450009

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-16 EDT 		5-day change 1st Jan Change
4,755 KRW -0.83% Intraday chart for Hansae Yes24 Holdings Co., Ltd +0.11% -2.96%
03-20 Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Correction, Hansa Biopharma, increase in number of shares and votes
AQ
Hansa Biopharma: increase in number of shares and votes
AQ
Hansa Biopharma interim report January-March 2024
AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
AQ
Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
AQ
Hansa Biopharma Year-end report January-December 2023
AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
AQ
Hansa Biopharma Nomination Committee formed
AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome
AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
AQ
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota
AQ
Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Hansa Biopharma Interim Report January-September 2023
AQ
Hansa Biopharma - Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study
AQ
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study
AQ
Hansa Biopharma - Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A016450 Stock
  4. News Hansae Yes24 Holdings Co., Ltd
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW